Health Economics›Graft versus host disease›Treatment cGVHD recurrent or refractory therapy

Treatment cGVHD recurrent or refractory therapy

Graft versus host disease · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib monotherapy Variant #01	—	R 80 133	28d	~41.3 mo	~30.3 mo	~45	~R 3 605 978 PFS proxy · indirect	17
Ruxolitinib monotherapy Variant #01	—	R 60 650	28d	—	—	—	—	2
Belumosudil monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Axatilimab monotherapy Variant #01 Partial	—	—	14d	—	—	—	—	—

4 of 4 regimens shown